Certain Radio Frequency Micro-Needle Dermatological Treatment Devices and Components Thereof; Commission Determination Not To Review an Initial Determination Terminating the Investigation in Its Entirety Based on a Settlement Agreement; Termination of the Investigation, 54175 [2019-21981]
Download as PDF
<![CDATA[
Federal Register / Vol. 84, No. 196 / Wednesday, October 9, 2019 / Notices
Issued: October 4, 2019.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2019–22058 Filed 10–8–19; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–1112]
Certain Radio Frequency Micro-Needle
Dermatological Treatment Devices and
Components Thereof; Commission
Determination Not To Review an Initial
Determination Terminating the
Investigation in Its Entirety Based on a
Settlement Agreement; Termination of
the Investigation
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that
the U.S. International Trade
Commission has determined not to
review an initial determination (‘‘ID’’)
(Order No. 45) of the presiding
administrative law judge (‘‘ALJ’’)
terminating the investigation as to the
remaining respondents, EndyMed
Medical Inc. of New York City, New
York and EndyMed Medical Ltd. of
Caesarea, Israel (‘‘Endy’’), based on a
settlement agreement. The investigation
is terminated.
FOR FURTHER INFORMATION CONTACT:
Clint Gerdine, Esq., Office of the
General Counsel, U.S. International
Trade Commission, 500 E Street SW,
Washington, DC 20436, telephone (202)
708–2310. Copies of non-confidential
documents filed in connection with this
investigation are or will be available for
inspection during official business
hours (8:45 a.m. to 5:15 p.m.) in the
Office of the Secretary, U.S.
International Trade Commission, 500 E
Street SW, Washington, DC 20436,
telephone (202) 205–2000. General
information concerning the Commission
may also be obtained by accessing its
internet server at https://www.usitc.gov.
The public record for this investigation
may be viewed on the Commission’s
electronic docket (EDIS) at https://
edis.usitc.gov. Hearing-impaired
persons are advised that information on
this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810.
SUPPLEMENTARY INFORMATION: The
Commission instituted this investigation
on May 15, 2018, based on a complaint
filed on behalf of Syneron Medical Ltd.
of Yokneam Illit, Israel; Candela
Corporation of Wayland, Massachusetts;
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:13 Oct 08, 2019
Jkt 250001
and Massachusetts General Hospital of
Boston, Massachusetts. 83 FR 22515–16
(May 15, 2018). The complaint, as
supplemented, alleges violations of
section 337 of the Tariff Act of 1930, as
amended, 19 U.S.C. 1337, based upon
the importation into the United States,
the sale for importation, and the sale
within the United States after
importation of certain radio frequency
micro-needle dermatological treatment
devices and components thereof by
reason of infringement of certain claims
of U.S. Patent Nos. 9,510,899 (‘‘the ’899
patent’’) and 9,095,357. The
Commission’s notice of investigation
named several respondents including
Endy; Invasix, Inc. and Inmode Md, Ltd.
of Lake Forest, California; Lumenis Ltd.
and Invasix, Ltd. of Yokneam, Israel;
Ilooda Co., Ltd. and Lutronic Corp. of
Gyeonggi-do, Republic of Korea; Cutera,
Inc. of Brisbane, California; Emvera
Technologies, LLC of Cedartown,
California; Rohrer Aesthetics, LLC of
Homewood, Alabama; Lutronic, Inc. of
Billerica, Massachusetts; Sung Hwan
E&B Co., Ltd. d/b/a SHEnB Co., Ltd. and
Jeisys Medical, Inc. of Seoul, Republic
of Korea; Aesthetics Biomedical, Inc. of
Phoenix, Arizona; Cartessa Aesthetics of
Hockessi, Delaware; Perigee Medical
Center LLC of Tracy, California; and
Pollogen, Ltd. of Tel Aviv-Jaffa, Israel.
The Office of Unfair Import
Investigations is not participating in the
investigation. All other respondents
have been terminated from the
investigation based on settlement
agreement. See Order No. 43 (July 23,
2019), unreviewed by Comm’n Notice
(Aug. 13, 2019); Order No. 23 (April 9,
2019), unreviewed by Comm’n Notice
(May 7, 2019); Order No. 20 (Mar. 26,
2019), unreviewed by Comm’n Notice
(Apr. 16, 2019); Order No. 18 (Mar. 20,
2019), unreviewed by Comm’n Notice
(Apr. 11, 2019); Order No. 16 (Mar. 6,
2019), unreviewed by Comm’n Notice
(Mar. 27, 2019); Order No. 15 (Feb. 22,
2019), unreviewed by Comm’n Notice
(Mar. 21, 2019).
On September 4, 2019, Complainants
and Endy jointly moved to terminate the
investigation based on a settlement
agreement.
On September 11, 2019, the ALJ
issued the subject ID (Order No. 45),
granting the joint motion terminating
the investigation in its entirety based on
settlement agreement. She found that
the motion for termination satisfied
Commission Rule 210.21, 19 CFR
210.21, and that termination of the
investigation is not contrary to the
public interest. No party petitioned for
review.
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
54175
The Commission has determined not
to review the subject ID. The
investigation is terminated.
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended, 19 U.S.C. 1337, and in Part
210 of the Commission’s Rules of
Practice and Procedure, 19 CFR part
210.
By order of the Commission.
Issued: October 3, 2019.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2019–21981 Filed 10–8–19; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
[CPCLO Order No. 010–2019]
Privacy Act of 1974; System of
Records
Federal Bureau of
Investigation, United States Department
of Justice.
ACTION: Notice of a Modified System of
Records.
AGENCY:
Pursuant to the Privacy Act of
1974 and Office of Management and
Budget (OMB) Circular No. A–108,
notice is hereby given that the Federal
Bureau of Investigation (FBI), a
component within the United States
Department of Justice (DOJ or
Department), proposes to modify a
system of records notice titled the
National Instant Criminal Background
Check System (NICS), JUSTICE/FBI–
018. The FBI proposes to consolidate
and replace the following previous
SORNs related to NICS: ‘‘National
Instant Criminal Background Check
System/FBI–018,’’ published at 63 FR
65223 (Nov. 25, 1998), 65 FR 78190
(Dec. 14, 2000), 66 FR 6676 (Jan. 22,
2001), 66 FR 8425 (Jan. 31, 2001), 66 FR
12959 (Mar. 1, 2001), and 82 FR 24147
(May 25, 2017). This notice also updates
the ‘‘PURPOSE(S) OF THE SYSTEM,’’
‘‘CATEGORIES OF INDIVIDUALS
COVERED BY THE SYSTEM,’’
‘‘CATEGORIES OF RECORDS IN THE
SYSTEM,’’ and ‘‘ROUTINE USES OF
RECORDS MAINTAINED IN THE
SYSTEM, INCLUDING CATEGORIES
OF USERS AND THE PURPOSES OF
SUCH USES’’ of the SORN.
DATES: In accordance with 5 U.S.C.
552a(e)(4) and (11), the public has 30
days in which to comment on the
routine uses, described below.
Therefore, please submit any comments
by November 8, 2019.
ADDRESSES: The public, OMB, and
Congress are invited to submit any
SUMMARY:
E:\FR\FM\09OCN1.SGM
09OCN1
]]>Agencies
[Federal Register Volume 84, Number 196 (Wednesday, October 9, 2019)]
[Notices]
[Page 54175]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-21981]
-----------------------------------------------------------------------
INTERNATIONAL TRADE COMMISSION
[Investigation No. 337-TA-1112]
Certain Radio Frequency Micro-Needle Dermatological Treatment
Devices and Components Thereof; Commission Determination Not To Review
an Initial Determination Terminating the Investigation in Its Entirety
Based on a Settlement Agreement; Termination of the Investigation
AGENCY: U.S. International Trade Commission.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the U.S. International Trade
Commission has determined not to review an initial determination
(``ID'') (Order No. 45) of the presiding administrative law judge
(``ALJ'') terminating the investigation as to the remaining
respondents, EndyMed Medical Inc. of New York City, New York and
EndyMed Medical Ltd. of Caesarea, Israel (``Endy''), based on a
settlement agreement. The investigation is terminated.
FOR FURTHER INFORMATION CONTACT: Clint Gerdine, Esq., Office of the
General Counsel, U.S. International Trade Commission, 500 E Street SW,
Washington, DC 20436, telephone (202) 708-2310. Copies of non-
confidential documents filed in connection with this investigation are
or will be available for inspection during official business hours
(8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S.
International Trade Commission, 500 E Street SW, Washington, DC 20436,
telephone (202) 205-2000. General information concerning the Commission
may also be obtained by accessing its internet server at https://www.usitc.gov. The public record for this investigation may be viewed
on the Commission's electronic docket (EDIS) at https://edis.usitc.gov.
Hearing-impaired persons are advised that information on this matter
can be obtained by contacting the Commission's TDD terminal on (202)
205-1810.
SUPPLEMENTARY INFORMATION: The Commission instituted this investigation
on May 15, 2018, based on a complaint filed on behalf of Syneron
Medical Ltd. of Yokneam Illit, Israel; Candela Corporation of Wayland,
Massachusetts; and Massachusetts General Hospital of Boston,
Massachusetts. 83 FR 22515-16 (May 15, 2018). The complaint, as
supplemented, alleges violations of section 337 of the Tariff Act of
1930, as amended, 19 U.S.C. 1337, based upon the importation into the
United States, the sale for importation, and the sale within the United
States after importation of certain radio frequency micro-needle
dermatological treatment devices and components thereof by reason of
infringement of certain claims of U.S. Patent Nos. 9,510,899 (``the
'899 patent'') and 9,095,357. The Commission's notice of investigation
named several respondents including Endy; Invasix, Inc. and Inmode Md,
Ltd. of Lake Forest, California; Lumenis Ltd. and Invasix, Ltd. of
Yokneam, Israel; Ilooda Co., Ltd. and Lutronic Corp. of Gyeonggi-do,
Republic of Korea; Cutera, Inc. of Brisbane, California; Emvera
Technologies, LLC of Cedartown, California; Rohrer Aesthetics, LLC of
Homewood, Alabama; Lutronic, Inc. of Billerica, Massachusetts; Sung
Hwan E&B Co., Ltd. d/b/a SHEnB Co., Ltd. and Jeisys Medical, Inc. of
Seoul, Republic of Korea; Aesthetics Biomedical, Inc. of Phoenix,
Arizona; Cartessa Aesthetics of Hockessi, Delaware; Perigee Medical
Center LLC of Tracy, California; and Pollogen, Ltd. of Tel Aviv-Jaffa,
Israel. The Office of Unfair Import Investigations is not participating
in the investigation. All other respondents have been terminated from
the investigation based on settlement agreement. See Order No. 43 (July
23, 2019), unreviewed by Comm'n Notice (Aug. 13, 2019); Order No. 23
(April 9, 2019), unreviewed by Comm'n Notice (May 7, 2019); Order No.
20 (Mar. 26, 2019), unreviewed by Comm'n Notice (Apr. 16, 2019); Order
No. 18 (Mar. 20, 2019), unreviewed by Comm'n Notice (Apr. 11, 2019);
Order No. 16 (Mar. 6, 2019), unreviewed by Comm'n Notice (Mar. 27,
2019); Order No. 15 (Feb. 22, 2019), unreviewed by Comm'n Notice (Mar.
21, 2019).
On September 4, 2019, Complainants and Endy jointly moved to
terminate the investigation based on a settlement agreement.
On September 11, 2019, the ALJ issued the subject ID (Order No.
45), granting the joint motion terminating the investigation in its
entirety based on settlement agreement. She found that the motion for
termination satisfied Commission Rule 210.21, 19 CFR 210.21, and that
termination of the investigation is not contrary to the public
interest. No party petitioned for review.
The Commission has determined not to review the subject ID. The
investigation is terminated.
The authority for the Commission's determination is contained in
section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, and
in Part 210 of the Commission's Rules of Practice and Procedure, 19 CFR
part 210.
By order of the Commission.
Issued: October 3, 2019.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2019-21981 Filed 10-8-19; 8:45 am]
BILLING CODE 7020-02-P
